Personalis, which provides a genome sequencing platform for cancer drug development, raised $135 million by offering 7.9 million shares at $17, above the range of $14 to $16. The company originally filed to offer 6.7 million shares.
Personalis plans to list on the Nasdaq under the symbol PSNL. Morgan Stanley, BofA Merrill Lynch and Cowen acted as joint book-running managers for the offering.
